Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Berghmans, Nele ^a   Heremans, Hubertine ^a   Li, Sandra ^a   Martens, Erik ^a   Matthys, Patrick ^a   Sorokin, Lydia ^b   Van Damme, Jo ^a   Opdenakker, Ghislain ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Central nervous system; Chemokines; Encephalitis; Leukocytes

Indexed keywords

ALPHA CHEMOKINE; ANTIINFLAMMATORY AGENT; CARBOXYLIC ACID DERIVATIVE; CHLORITE OXIDIZED OXYAMYLOSE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON; MESSENGER RNA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOASSAY; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE DEVIATION; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTE FUNCTION AND CHARACTERISTICS; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE;

EID: 84867743276     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-243     Document Type: Article

References (37)

1. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993, 36:432-440. 10.1002/jnr.490360409, 7505841.
2. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002, 20:101-123. 10.1146/annurev.immunol.20.081701.141316, 11861599.
3. Bartholomäus I, Kawakami N, Odoardi F, Schläger C, Miljkovic D, Ellwart JW, Klinkert WE, Flügel-Koch C, Issekutz TB, Wekerle H, Flügel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98. 10.1038/nature08478, 19829296.
4. Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, Robenek H, Tryggvason K, Song J, Korpos E, Loser K, Beissert S, George-Labouesse E, Sorokin LM. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med 2009, 15:519-527. 10.1038/nm.1957, 19396173.
5. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010, 10:712-723. 10.1038/nri2852, 20865019.
6. Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003, 2:747-756. 10.1016/S1474-4422(03)00587-8, 14636780.
7. Chofflon M. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 2000, 7:369-380. 10.1046/j.1468-1331.2000.00057.x, 10971595.
8. Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005, 1:34-44. 10.1038/ncpneuro0016, 16932490.
9. Yong VW, Chabot S, Stüve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998, 51:682-689. 10.1212/WNL.51.3.682, 9748010.
10. Barholomé EJ, Van Aelst I, Koyen E, Kiss R, Willems F, Goldman M, Opdenakker G. Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by interferon-beta. J Interferon Cytokine Res 2001, 21:495-501. 10.1089/10799900152434367, 11506743.
11. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988, 140:1506-1510.
12. van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, Dijkstra CD. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 1998, 84:14-23. 10.1016/S0165-5728(97)00207-5, 9600704.
13. De Clercq E, Merigan TC. Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature 1969, 222:1148-1152. 10.1038/2221148a0, 4307027.
14. De Somer P, De Clercq E, Billiau A, Schonne E, Claesen M. Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol 1968, 2:886-893. 375708, 5725320.
15. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006, 177:7505-7509.
16. Billiau A, Desmyter J, De Somer P. Antiviral activity of chlorite-oxidized oxyamylose, a polyacetal carboxylic acid. J Virol 1970, 5:321-328. 376009, 4314554.
17. De Palma AM, Thibaut HJ, Li S, Van Aelst I, Dillen C, Swinnen M, Verbeken E, Neyts J, Opdenakker G. Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for Coxsackie virus B4-induced pancreatitis. J Pathol 2009, 217:633-641. 10.1002/path.2501, 19142976.
18. Li S, Martens E, Dillen C, Van den Steen PE, Opdenakker G. Virus entry inhibition by chlorite-oxidized oxyamylose versus induction of antiviral interferon by poly(I:C). Biochem Pharmacol 2008, 76:831-840. 10.1016/j.bcp.2008.07.022, 18703022.
19. Li S, Starckx S, Martens E, Dillen C, Lamerant-Fayel N, Berghmans N, Gouwy M, van Pel M, Heremans H, Kieda C, Fibbe WE, Billiau A, Van Damme J, Opdenakker G. Myeloid cells are tunable by a polyanionic polysaccharide derivative and co-determine host rescue from lethal virus infection. J Leukocyte Biol 2010, 88:1017-1029. 10.1189/jlb.1109724, 20709940.
20. Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol 1997, 159:1418-1428.
21. Claes P, Billiau A, De Clercq E, Desmyter J, Schonne E, Vanderhaeghe H, De Somer P. Polyacetal carboxylic acids: a new group of antiviral polyanions. J Virol 1970, 5:313-320. 376008, 4314553.
22. Loos T, Mortier A, Proost P. Chapter 1. Isolation, identification and production of posttranslationally modified chemokines. Methods Enzymol 2009, 461:3-29.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
24. Heremans H, Billiau A, Colombatti A, Hilgers J, De Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 1978, 21:925-930. 422085, 213392.
25. Dijkmans R, Martens E, Beuken E, Cornette F, Dillen C, Heremans H, Boraschi D, Billiau A. Murine interferon-γ/interleukin-1 fusion protein used as antigens for the generation of hybridomas producing monoclonal anti-interleukin-1 antibodies. Cytokine 1991, 3:134-140. 10.1016/1043-4666(91)90034-B, 1909588.
26. Kelchtermans H, Struyf S, De Klerck B, Mitera T, Alen M, Geboes L, Van Balen M, Dillen C, Put W, Gysemans C, Billiau A, Van Damme J, Matthys P. Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. J Leukoc Biol 2007, 81:1044-1053. 10.1189/jlb.0806486, 17200147.
27. Forde EA, Dogan RN, Karpus WJ. CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function. J Neuroimmunol 2011, 236:17-26. 10.1016/j.jneuroim.2011.04.008, 3139027, 21575994.
28. Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation 2005, 29:2-17.
29. Allen SJ, Baker D, O'Neill JK, Davison AN, Turk JL. Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Cell Immunol 1993, 146:335-350. 10.1006/cimm.1993.1031, 8174174.
30. McColl SR, Staykova MA, Wozniak A, Fordham S, Bruce J, Willenborg DO. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol 1998, 161:6421-6428.
31. Wuyts A, Haelens A, Proost P, Lenaerts JP, Conings R, Opdenakker G, Van Damme J. Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J Immunol 1996, 157:1736-1743.
32. Piccard H, Berghmans N, Korpos E, Dillen C, Van Aelst I, Li S, Martens E, Liekens S, Noppen S, Van Damme J, Sorokin L, Opdenakker G. Glycosaminoglycan mimicry by COAM reduces melanoma growth through chemokine induction and function. Int J Cancer 2012, 131:E425-E436. 10.1002/ijc.26465, 21953247.
33. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans-as exemplified with chemokines. Annu Rev Biochem 2005, 74:385-410. 10.1146/annurev.biochem.72.121801.161747, 15952892.
34. Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005, 16:625-636. 10.1016/j.cytogfr.2005.04.006, 15990353.
35. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009, 361:1067-1074. 10.1056/NEJMoa0904267, 3077718, 19741227.
36. Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009, 361:1081-1087. 10.1056/NEJMoa0810316, 19741229.
37. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009, 361:1075-1080. 10.1056/NEJMoa0810257, 19741228.